The aim of this study was to perform quantitative SPECT/CT of prostate cancer patients after [225Ac]Ac-PSMA-I&T therapy, exploiting all available photopeaks, to compare the pharmacokinetics of the two 225Ac daughters 213Bi and 221Fr. The gene discussed is FOLH1; the disease is prostate carcinoma.